ArticleJournal of cellular and molecular medicine2025
Chemerin's Role in Endometrial Dysfunction: Insights From Transcriptomic Analysis.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Endometrium, the lining of the uterus, changes dynamically in response to fluctuations in ovarian hormones. The proper endocrine environment regulates endometrial functions: menstruation and supporting pregnancy. Obesity is closely related to endometrial dysfunction, which seriously affects women's health and fertility, but the pathological mechanism is unknown. Chemerin is an adipokine involved in multiple biological events such as immunity and metabolism by acting on its functional receptors. This study aimed to characterise the effects of chemerin on human endometrial epithelial cells by RNA-Seq. 12Z cells were utilised as the model because immunoblot results showed that they expressed endometrial markers, epithelial markers and functional receptors for chemerin. Principal component analysis (PCA) showed that chemerin treatment significantly altered the transcriptome. Differential Expression Analysis found 388 significant differentially expressed genes (DEG) in the chemerin treatment group compared with the controls. Gene Set Enrichment Analysis (GSEA) showed that chemerin inhibited lipid metabolism and induced the epithelial-mesenchymal transition (EMT)-like process and cellular senescence. More importantly, GSEA and immunoblots showed that chemerin restrained the STAT3 signalling pathway, which is required for endometrial receptivity establishment. Collectively, these findings provide new evidence that over-produced chemerin underlying the endometrial dysfunctions in obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.